OPEN Foundation

OPEN Foundation

Special issue about psychedelics in 'The Psychologist'

The British Psychological Association recently published a special issue of their accompanying journal The Psychologist (September 2014, vol. 27) devoted to the rising popularity of research into psychedelics. This is the first time such a lengthy publication, illuminating the intricacies of the psychedelic experience, has appeared in the journal.

David Nutt claims, in the first article of the issue, that the scientific disinterestedness of the past can be explained by society’s attempt to deny psychedelics their “value and importance” in the study of altered states for moral reasons. The political reasoning is the following one: how can we not but condemn research into psychedelics if this poses the risk that it would legitimize recreational use? However, Nutt asserts that despite the possible societal risk “(t)he failure of the scientific community, particularly neuroscientists, to protest the denial of research on hallucinogens is one of the most disturbing failures of science leadership in the past century, and it must be rectified. Psychologists and other neuroscientists must demand the right to study these drugs” (2014).

Many neuroscientists did not wait for Nutt’s summoning to start unraveling the relationship between psychedelic drugs and the human brain. In How do psychedelics work on the brain? (the second article) Carhart-Harris, Kaelen and Nutt (2014) describe the psychedelic experience, starting at the neurotransmitter level and ending at the neuronal large-scale systems of the brain. The obvious question for psychology (as is stated in the title of the special issue) is whether the neuronal level can tell us anything about the psychedelic experience that is within our field of meaning or, as Jameson puts it, our “cognitive mapping” (1991). The title of the special issue suggests that human psychology, by adopting neuroscientific knowledge, can do just that.

In the third article, Vaughan Bell (2014) opposes this approach and asks a different question: what can we learn from the ways in which other societies approach hallucinogenic drugs? Bell asserts that “drug-induced hallucinations are often discussed as if they can be entirely understood in terms of their chemical action in the brain”. In Bell’s view it is not the brain, but rather culture and the relationship between the individual and her social context where the real magic happens.

The fourth article, by Henry David Abraham (2014), connects the three previous ones by describing the author’s investigations into hallucinogen persisting perception disorder (HPPD). Here Abraham gives a phenomenological reading and tries to describe the complex dynamic between the neuronal and the psychological dimensions of HPPD.

Charles Grob, Ira Byock and Erica Rex, in the fifth article Viewpoints: Experiences of hallucinogen treatment (2014), extend the view posited by Abraham and give an account of the exciting ‘new’ realm of psychedelic treatment and psychological assistance. “Multiple participants”, says Byock, “report not mere alleviated anxiety or depression, but also an enduring sense of well-being. Some expressed feeling at peace, grateful for their lives, forgiving toward others and toward themselves and being less fearful and more confident about the future”. The treatment intervention for “existential anxiety” proposed by Grob (2014) is seen as just one of the many possible applications of psychedelic substances.

All articles appear in the September edition of The Psychologist (volume 27, part 9) “A brave new world for psychology?”


 
References
Abraham, H. D. (2014). When the trip doesn’t end. The Psychologist, 27(9), 670-673.
Bell, V. (2014). Cultures of chemically induced hallucinations. The Psychologist, 27(9), 666-669.
Carthart-Harris, R., Kaelen, M., & Nutt, D. (2014). How do hallucinogens work on the brain? The Psychologist, 27(9), 662-665.
Grob, C.S., Byock, I.R., Rex, E. (2014). Viewpoints: Experiences of hallucinogen treatment. The Psychologist, 27(9), 676-679
Jameson, F. (1991). Postmodernism, or, the cultural logic of late capitalism. Durham, NC: Duke University Press.
Nutt, D. (2014). A brave new world for psychology? The Psychologist, 27(9), 658-661.

Themanummer over psychedelica in ‘The Psychologist’

Recentelijk heeft de Britse Psychological Association een speciaal themanummer van ´The Psychologist´ (September 2014, vol. 27) aan de toenemende populariteit van onderzoek naar psychedelica gewijd. Dit is de eerste keer dat er een uitgebreide publicatie over de complexiteit van de psychedelische ervaring verscheen in het blad.

David Nutt (2014) stelt, in het eerste artikel van het nummer, dat de wetenschappelijke desinteresse van het verleden verklaard kan worden door de maatschappelijke poging om psychedelica van hun “waarde en belang” te ontdoen om morele redenen. De politieke redenering gaat als volgt: hoe kunnen we anders dan het onderzoek naar psychedelica veroordelen wanneer het risico bestaat dat dit onderzoek recreatief gebruik zou kunnen legitimeren? Ondanks de mogelijke maatschappelijke risico’s stelt Nutt dat “het falen van de wetenschappelijke gemeenschap (met name neurowetenschappers) om te protesteren tegen het verbod op onderzoek naar hallucinogenen, één van de meest ontstellende vergissingen van de laatste eeuw is, en dat die ongedaan moet worden gemaakt. Psychologen en andere neurowetenschappers moeten het recht opeisen om deze drugs te bestuderen” (2014).

Vele neurowetenschappers hebben niet gewacht tot Nutt met deze oproep kwam om te beginnen met het ontrafelen van de relatie tussen psychedelische drugs en de menselijke hersenen. In How do psychedelics work on the brain? (het tweede artikel) beschrijven Carhart-Harris, Kaelen en Nutt (2014) de psychedelische ervaring, beginnend bij het niveau van neurotransmitters en eindigend bij de grootschalige neuronale systemen in het brein. De voor de hand liggende vraag voor de psychologie (zoals aangegeven in de titel van het themanummer) is of de neuronale dimensie ons iets kan vertellen over de psychedelische ervaring dat nog binnen ons gebied van betekenis ligt, of zoals Jameson het stelt, “our cognitive mapping” (1991).

In het derde artikel neemt Vaughan Bell (2014) een andere invalshoek en stelt hij de vraag: wat kunnen we leren uit de manieren waarop andere culturen omgaan met hallucinogene drugs? Bell stelt dat “drugs-geïnduceerde hallucinaties vaak worden onderzocht alsof ze volledig kunnen worden begrepen als chemische reacties in het brein”. In Bell’s gedachtegoed is het niet in het brein, maar juist in de cultuur en de relatie tussen het individuele en de sociale context waar de interessante effecten plaatsvinden.

Het vierde artikel, geschreven door Henry David Abraham (2014), verbindt de drie eerdere artikelen door het onderzoek van de auteur naar HPPD (hallucinogen persisting perception disorder) te beschrijven. Abraham geeft hierin een fenomenologische beschrijving van de complexe dynamiek tussen de neuronale en de psychologische dimensies van HPPD.

Charles Grob, Ira Byock en Erica Rex breiden, in het vijfde artikel Viewpoints: Experiences of hallucinogen treatment (2014), de denkwijze van Abraham uit door inzicht te geven in het ‘nieuwe’ veld van psychedelische therapie. “Verschillende deelnemers”, zegt Byock, “rapporteren niet alleen een vermindering van angst of depressie, maar ook een langdurig gevoel van welzijn. Sommigen uiten een gevoel van vrede, dankbaarheid voor hun leven, vergiffenis naar anderen en naar henzelf, en minder angst en meer zekerheid over de toekomst”. De door Grob beschreven behandelinterventie voor “existentiële angst” wordt gezien als slechts een van de vele mogelijke toepassingen van psychedelica.

Alle artikelen zijn in de september editie van The Psychologist verschenen (volume 27, 9) “A brave new world for psychology?”


 
Referenties
Abraham, H. D. (2014). When the trip doesn’t end. The Psychologist, 27(9), 670-673.
Bell, V. (2014). Cultures of chemically induced hallucinations. The Psychologist, 27(9), 666-669.
Carthart-Harris, R., Kaelen, M., & Nutt, D. (2014). How do hallucinogens work on the brain? The Psychologist, 27(9), 662-665.
Grob, C.S., Byock, I.R., Rex, E. (2014). Viewpoints: Experiences of hallucinogen treatment. The Psychologist, 27(9), 676-679
Jameson, F. (1991). Postmodernism, or, the cultural logic of late capitalism. Durham, NC: Duke University Press.
Nutt, D. (2014). A brave new world for psychology? The Psychologist, 27(9), 658-661.

Back to the future: A return to psychedelic treatment models for addiction

Abstract

The discovery of the 5HT2aR agonist hallucinogen (i.e. classic psychedelic) lysergic acid diethylamide (LSD) by Albert Hofmann in 1943 was a global watershed event. Not only did it spark wide interest in the nature of consciousness and the role of neurotransmission in brain function, it opened new avenues of potential treatment for a range of mental health conditions (Hofmann, 2013). The scientific community of the 1950s through the early 1970s responded to Hofmann’s discovery by producing more than 1000 manuscripts describing the treatment of 40,000 patients (Nutt et al., 2013). Despite promising if not remarkable indications of efficacy (Krebs and Johansen, 2012; Savage and McCabe, 1973),sensationalized reports of recreational LSD use prompted legal restrictions that ultimately rendered research with LSD and …

Hendricks, P. S. (2014). Back to the future: A return to psychedelic treatment models for addiction. Journal of Psychopharmacology, 28(11), 981-982. http://dx.doi.org/10.1177/0269881114550935
Link to full text

LSD enhances suggestibility in healthy volunteers

Abstract

Rationale
Lysergic acid diethylamide (LSD) has a history of use as a psychotherapeutic aid in the treatment of mood disorders and addiction, and it was also explored as an enhancer of mind control.

Objectives
The present study sought to test the effect of LSD on suggestibility in a modern research study.

Methods
Ten healthy volunteers were administered with intravenous (i.v.) LSD (40–80 μg) in a within-subject placebo-controlled design. Suggestibility and cued mental imagery were assessed using the Creative Imagination Scale (CIS) and a mental imagery test (MIT). CIS and MIT items were split into two versions (A and B), balanced for ‘efficacy’ (i.e. A≈B) and counterbalanced across conditions (i.e. 50 % completed version ‘A’ under LSD). The MIT and CIS were issued 110 and 140 min, respectively, post-infusion, corresponding with the peak drug effects.

Results
Volunteers gave significantly higher ratings for the CIS (p = 0.018), but not the MIT (p = 0.11), after LSD than placebo. The magnitude of suggestibility enhancement under LSD was positively correlated with trait conscientiousness measured at baseline (p = 0.0005).

Conclusions
These results imply that the influence of suggestion is enhanced by LSD. Enhanced suggestibility under LSD may have implications for its use as an adjunct to psychotherapy, where suggestibility plays a major role. That cued imagery was unaffected by LSD implies that suggestions must be of a sufficient duration and level of detail to be enhanced by the drug. The results also imply that individuals with high trait conscientiousness are especially sensitive to the suggestibility-enhancing effects of LSD.

Carhart-Harris, R. L., Kaelen, M., Whalley, M. G., Bolstridge, M., Feilding, A. & Nutt, D.J. (2014). LSD enhances suggestibility in healthy volunteers. Psychopharmacology. http://dx.doi.org/10.1007/s00213-014-3714-z
Link to full text

Psilocybine tegen tabaksverslaving

a6_upinsmoke_508x200De resultaten van een pilotstudie waarin therapie in combinatie met psilocybine werd ingezet bij de behandeling van een tabaksverslaving [fusion_builder_container hundred_percent=”yes” overflow=”visible”][fusion_builder_row][fusion_builder_column type=”1_1″ background_position=”left top” background_color=”” border_size=”” border_color=”” border_style=”solid” spacing=”yes” background_image=”” background_repeat=”no-repeat” padding=”” margin_top=”0px” margin_bottom=”0px” class=”” id=”” animation_type=”” animation_speed=”0.3″ animation_direction=”left” hide_on_mobile=”no” center_content=”no” min_height=”none”][1] bieden een hoopvol perspectief in de strijd tegen één van de meest hardnekkige en dodelijkste verslavingen van deze tijd [2].

In het onderzoek aan de Johns Hopkins University School of Medicine werd een cognitieve gedragstherapie aangevuld met maximaal drie psilocybinesessies. Van de vijftien rokers die met het onderzoek meededen lukte het er twaalf (80%) na de behandeling een halfjaar gestopt te blijven [3]. De deelnemers ervoeren een toename van controle over hun rookgedrag, een verhoogde mate van spiritualiteit en een toegenomen gevoel van persoonlijk welzijn. Een interessante bevinding is dat bij de drie deelnemers die het niet was gelukt te stoppen, er na zes maanden wél een vermindering in het aantal gerookte sigaretten per dag te zien was.

Vanwege het ontbreken van een controlegroep in deze experimentele studie is het (nog) niet mogelijk om het veelbelovende effect van de behandelmethode toe te schrijven aan de werking van psilocybine. Desalniettemin duiden deze eerste bevindingen op een gunstiger behandelresultaat van psilocybine in combinatie met cognitieve gedragstherapie (80% succesratio) dan een behandeling met behulp van reguliere farmaca, zoals buproprion (succesratio rond de 25%) en varenicline (succesratio rond de 34%) [4], of in vergelijking met een combinatie van buproprion, nicotinevervanging, en een intensieve vorm van cognitieve gedragstherapie (succesratio rond de 50%) [5][6]. Vervolgonderzoek is wenselijk om het behandelpotentieel van psilocybine over het volle domein te kunnen beoordelen.

Het idee om verslavingen tegen te gaan met behulp van psychedelica is overigens niet nieuw. In de jaren ’50 en ’60 werd er al veel onderzoek verricht naar de therapeutische potentie van deze middelen. De geïnteresseerde lezer kan zich wenden tot een meta-analyse van Teri Krebs (2012), waarin op basis van de resultaten van zes van deze studies wordt geconcludeerd dat de behandeling van alcoholisme met behulp van LSD erg effectief leek te zijn.


 
[1] Johnson, Garcia-Romeu, Cosimano, & Griffiths (2014)
[2] Wereldgezondheidsorganisatie (2011)
[3] Er moet rekening gehouden worden met het feit dat enkele deelnemers aangaven tussen de laatste behandelsessie en de nameting zes maanden later een terugval te hebben gehad (lees: hebben gerookt), maar zelf in staat waren deze te corrigeren.
[4] Gonzales et al., 2014; Jorenby et al., 2014
[5] Hall et al., 2009; Killen et al., 2008
[6] Succesratio’s zijn gebaseerd op een 7-daagse puntprevalentie abstinentie na zes maanden. Zowel op basis van zelfrapportage als op basis van een urine- en ademtest.
 
Referenties
Gonzales, D., Rennard, S. I., Nides, M., Oncken, C., Azoulay, S., Billing, C. B., … Reeves, K. R. (2014). Varenicline, an ␣ 4 ␤ 2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation, 296(1), 47–55.
Hall, S. M., Humfleet, G. L., Muñoz, R. F., et al. (2009). Extended treatment of older cigarette smokers. Addiction, 104, 1043-1052
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology (Oxford, England), (September). doi:10.1177/0269881114548296
Jorenby, D. E., Hays, J. T., Rigotti, N. A., Azoulay, S., Watsky, E. J., Williams, K. E., … Reeves, K. R. (2014). Efficacy of Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking CessationA Randomized Controlled Trial. JAMA, 296, 56-63.
Killen, J. D., Fortmann, S. P., Schatzberg, A. F., et al. (2008). Extended cognitive behavior therapy for cigarette smoking cessation. Addiction, 103, 1381-1390.
Krebs, T. S., & Johansen, P.-Ø. (2012). Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. Journal of Psychopharmacology (Oxford, England), 26(7), 994–1002. doi:10.1177/0269881112439253[/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]

Psilocybin against tobacco addiction

A positive treatment perspective for one of the current most persistent and deadliest addictions comes from a psilocybin-assisted smoking cessation study carried out at the Johns Hopkins University School of Medicine in Maryland, USA [2].

The form of treatment consisted of up to three psilocybin sessions additional to cognitive behavioral therapy. Twelve out of fifteen participants (80%) succeeded in quitting their habit after this treatment for a minimum of six months [3]. Participants experienced an increased faith to effectively deal with the addiction, a heightened spiritual awareness and an uplifted state of overall well-being. An interesting finding was that, although three participants didn’t succeed in quitting, this group turned out smoking less cigarettes a day six months after the beginning of the treatment.

Because of the study design lacking a control group, it is not (yet) possible to solely ascribe the therapeutic effect of the treatment to the characteristics of psilocybin. Nevertheless, these results promise a better treatment perspective for psilocybin combined with cognitive behavioral therapy than for regular treatment options. The success rate in this study being 80%, compared to 25% to 34% when treated with buproprion or varenicline respectively [4], or compared to around 50% when treated with a combination of bupropion, nicotine replacement, and intensive cognitive behavioral therapy [5][6]. More scientific studies would be necessary in order to understand the full potential of treating smoking addiction with psilocybin or other pharmacons that have their mechanism of action on the 5-HT2A-receptor.

The idea of using psychedelics to fight addiction is nothing new. In the 50s and 60s there were a lot of research projects focusing on the therapeutic potential of these compounds. The interested reader might want to take a look at a meta-analysis by Teri Krebs (2012), which, based on six of these studies, concluded that the treatment of alcoholism using LSD seemed to be very effective.


[1] World Health Organization (2011)
[2] Johnson, Garcia-Romeu, Cosimano, & Griffiths (2014)
[3] The notion should be considered that several participants indicated to have a relapse period between the last psilocybin session and six month follow-up, but that they were able to correct it themselves and continued as non-smokers until follow-up.
[4] Gonzales et al., 2014; Jorenby et al., 2014
[5] Hall et al., 2009; Killen et al., 2008
[6] Success rates are based on 7 day point prevalence abstinence measures of smoking behavior. Gathered by self-report and urine- and breath analyzes.

References
Gonzales, D., Rennard, S. I., Nides, M., Oncken, C., Azoulay, S., Billing, C. B., … Reeves, K. R. (2014). Varenicline, an ␣ 4 ␤ 2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation, 296(1), 47–55.
Hall, S. M., Humfleet, G. L., Muñoz, R. F., et al. (2009). Extended treatment of older cigarette smokers. Addiction, 104, 1043-1052
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology (Oxford, England), (September). doi:10.1177/0269881114548296
Jorenby, D. E., Hays, J. T., Rigotti, N. A., Azoulay, S., Watsky, E. J., Williams, K. E., … Reeves, K. R. (2014). Efficacy of Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking CessationA Randomized Controlled Trial. JAMA, 296, 56-63.
Killen, J. D., Fortmann, S. P., Schatzberg, A. F., et al. (2008). Extended cognitive behavior therapy for cigarette smoking cessation. Addiction, 103, 1381-1390.
Krebs, T. S., & Johansen, P.-Ø. (2012). Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. Journal of Psychopharmacology (Oxford, England), 26(7), 994–1002. doi:10.1177/0269881112439253[/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]

Johns Hopkins "Bad Trip" Survey

badtripsgraphic508The Psilocybin Research Team at Johns Hopkins needs your help! To study the complex, and often challenging experiences usually referred to as ´bad trips´, the Psilocybin Research Team is conducting an anonymous, web-based survey into this very phenomena. If you’ve ever had such an experience, they would greatly appreciate it if you participate. Also if you know anyone that has had such an experience and would be interested in participating, don’t hesitate to pass on the link.

Please participate and share: http://www.shroomsurvey.com

BACKGROUND: As you may remember, last year we conducted an internet survey characterizing challenging experiences (so called “ bad trips”) after taking psilocybin. The results of that survey have been quite interesting and will result in two or more publications. As part of the analysis of data from that survey, we have developed a second version of the survey that should permit the final development of a psychometrically rigorous Challenging Effect Questionnaire that we hope will make a significant contribution to the scientific understanding of psilocybin. This work complements our published and ongoing work validating a questionnaire assessing psilocybin occasioned mystical experiences.

Johns Hopkins “Bad Trip” Onderzoek

badtripsgraphic508Het Psilocybine onderzoeksteam van Johns Hopkins heeft hulp nodig. Om de complexe, en vaak uitdagende ‘bad trip’ ervaring te bestuderen, is het Psilocybine Onderzoeksteam bezig met een anonieme enquête op het internet. Mocht je ooit een dergelijke ervaring hebben gehad, dan stellen de onderzoekers het zeer op prijs als je de enquête invult. Heb je zelf nooit een ‘bad trip’ gehad, maar ken je mensen die er wel bekend mee zijn, twijfel dan niet om de link door te sturen.

Doe mee en deel: http://www.shroomsurvey.com

ACHTERGROND: Zoals je wellicht kunt herinneren, hebben we het afgelopen jaar een internetonderzoek gedaan om uitdagende ervaringen (zogenaamde ‘bad trips’) na het nemen van psilocybine in kaart te brengen. De resultaten van deze vragenlijst waren erg interessant en zullen resulteren in twee of meer publicaties. Als onderdeel van de analyse van de data van dat onderzoek, hebben we een tweede versie van de vragenlijst ontwikkeld die moet leiden tot de uiteindelijke ontwikkeling van een psychometrisch sterke ‘Challenging Effect Questionnaire’, waarvan we hopen dat het een significante bijdrage zal gaan leveren aan het wetenschappelijk inzicht op het gebied van psilocybine. Dit werk zal een aanvulling zijn op ons gepubliceerde en lopende werk naar het valideren van een vragenlijst die door psilocybine geïnduceerde mystieke ervaringen in kaart kan brengen.

The role of ketamine in treatment-resistant depression: a systematic review

Abstract

BACKGROUND:

At least 10-20% of the patients suffering from depression meet criteria for treatment-resistant depression (TRD). In the last decades, an important role of glutamate in mood modulation has been hypothesized and ketamine, a non noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptors, has been demonstrated to be effective in both MDD and TRD. However, concerns emerged about the optimal dosage, and frequency of administration of this treatment.

METHODS:

aiming to systematically review the current literature focusing on the main pharmacological properties and impact of ketamine in TRD, a detailed literature search in PubMed/Medline and ScienceDirect databases was conducted. Twenty-four manuscripts including a total of 416 patients fulfilled inclusion criteria.

RESULTS:

Most studies demonstrated that the NMDA antagonist ketamine has rapid antidepressant effects in TRD patients, confirming the active role of glutamate in the pathophysiology of this complex condition. Ketamine has been demonstrated to be rapidly effective and was associated with a significant clinical improvement in depressive symptoms within hours after administration. Also, ketamine was also found to be effective in reducing suicidality in TRD samples.

LIMITATIONS:

The long-term efficacy of ketamine has not been investigated by most studies. The psychotomimetic properties may complicate the application of this pharmacological agent.

CONCLUSIONS:

Ketamine may be considered a valid and intriguing antidepressant option for the treatment of TRD. Further studies are needed to evaluate its long-term antidepressant efficacy in patients with TRD.

Serafini, G., H Howland, R., Rovedi, F., Girardi, P., & Amore, M. (2014). The Role of Ketamine in Treatment-Resistant Depression: A Systematic Review. Current neuropharmacology, 12(5), 444-461. https://dx.doi.org/10.2174/1570159X12666140619204251
Link to full text

Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction

Abstract

Despite suggestive early findings on the therapeutic use of hallucinogens in the treatment of substance use disorders, rigorous follow-up has not been conducted. To determine the safety and feasibility of psilocybin as an adjunct to tobacco smoking cessation treatment we conducted an open-label pilot study administering moderate (20 mg/70 kg) and high (30 mg/70 kg) doses of psilocybin within a structured 15-week smoking cessation treatment protocol. Participants were 15 psychiatrically healthy nicotine-dependent smokers (10 males; mean age of 51 years), with a mean of six previous lifetime quit attempts, and smoking a mean of 19 cigarettes per day for a mean of 31 years at intake. Biomarkers assessing smoking status, and self-report measures of smoking behavior demonstrated that 12 of 15 participants (80%) showed seven-day point prevalence abstinence at 6-month follow-up. The observed smoking cessation rate substantially exceeds rates commonly reported for other behavioral and/or pharmacological therapies (typically <35%). Although the open-label design does not allow for definitive conclusions regarding the efficacy of psilocybin, these findings suggest psilocybin may be a potentially efficacious adjunct to current smoking cessation treatment models. The present study illustrates a framework for future research on the efficacy and mechanisms of hallucinogen-facilitated treatment of addiction.

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 28(11), 983-992. http://dx.doi.org/10.1177/0269881114548296
Link to full article

interested in becoming a trained psychedelic-assisted therapist?

Indigenous Talk: Fulni-ô Culture & Jurema - Online Event - Dec 12th